Annual revenue of CanSino Biologics Inc. 2017-2021
the international market, thanks to the export sales of Convidecia, the company's single-dose COVID-19 vaccine.
In 2021, the Tianjin-based Chinese vaccine company Cansino Biologics Inc. reported annual revenue of almost 4.3 billion yuan, representing an increase of more than 23,000 percent from the previous year. The company generated little revenue between 2017 and 2019 and suffered from losses before the COVID-19 pandemic. More than 70 percent of the CanSino's revenue in 2021 came from